Calcimimetic R-568 and Its Enantiomer S-568 Increase Nitric Oxide Release in Human Endothelial Cells
Open Access
- 25 January 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (1) , e30682
Abstract
Calcimimetics, such as R-568, are thought to activate G protein-linked Ca2+-sensing receptor (CaSR) by allosterically increasing the affinity of the receptor for Ca2+ allowing for efficient control of uremic hyperparathyroidism. Several recent studies suggest they possess additional vascular actions. Although it has been postulated that calcimimetics may have a direct effect on CaSR in the blood vessels, further studies are needed to elucidate their vascular CaSR-dependent versus CaSR-independent effects. Focusing on human umbilical vein endothelial cells (HUVECs), we studied the CaSR expression and distribution by Immunofluorescence and Western Blot analysis. CaSR function was evaluated by measuring the potential effect of calcimimetic R-568 and its enantiomer S-568 upon the modulation of intracellular Ca2+ levels (using a single cell approach and FURA-2AM), in the presence or absence of Calhex-231, a negative modulator of CaSR. To address their potential vascular functions, we also evaluated R- and S-568-stimulated enzymatic release of Nitric Oxide (NO) by DAF-2DA, by Nitric Oxide Synthase (NOS) radiometric assay (both in HUVECs and in Human Aortic Endothelial Cells) and by measuring eNOS-ser1177 phosphorylation levels (Immunoblotting). We show that, although the CaSR protein was expressed in HUVECs, it was mainly distributed in cytoplasm while the functional CaSR dimers, usually localized on the plasma membrane, were absent. In addition, regardless of the presence or absence of Calhex-231, both R- and S-568 significantly increased intracellular Ca2+ levels by mobilization of Ca2+ from intracellular stores, which in turn augmented NO release by a time- and Ca2+-dependent increase in eNOS-ser1177 phosphorylation levels. Taken together, these data indicate that in human endothelium there is no stereoselectivity in the responses to calcimimetics and that CaSR is probably not involved in the action of R- and S-568. This suggests an additional mechanism in support of the CaSR-independent role of calcimimetics as vasculotrope agents.Keywords
This publication has 40 references indexed in Scilit:
- Acute cardiovascular effects of the calcimimetic R-568 and its enantiomer S-568 in ratsPediatric Nephrology, 2009
- Evidence for the presence of GPRC6A receptors in rat mesenteric arteriesCell Calcium, 2008
- Nitric oxide deficiency in chronic kidney diseaseAmerican Journal of Physiology-Renal Physiology, 2008
- Allosteric Modulation of the Calcium-Sensing ReceptorCurrent Neuropharmacology, 2007
- The rat GPRC6A: Cloning and characterizationGene, 2007
- Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients2006
- Pharmacological activity of calcimimetic NPS R-568 administered intravenously in rats: dose dependency.2006
- Regulation of parathyroid hypertensive factor secretion by Ca2+ in spontaneously hypertensive rat parathyroid cellsAmerican Journal of Hypertension, 2004
- Regulation of Endothelial Nitric Oxide Synthase: Location, Location, LocationAnnual Review of Physiology, 2002
- Evidence for a Calcium-Sensing Receptor in the Vascular Smooth Muscle Cells of the Spiral Modiolar ArteryThe Journal of Membrane Biology, 2000